CAS: 89031-84-5; (3-Bromopropoxy)-Tert-Butyldimethylsilane

相似化合物

627-18-9 89043-32-3 86864-60-0

上下游产品

CAS号18162-48-6 叔丁基二甲基氯硅烷 | CAS号627-18-9 3-溴-1-丙醇 | CAS号69739-34-0 叔丁基二甲基硅基三氟甲磺酸酯 | CAS号73842-99-6 3-((叔丁基二甲基甲硅烷基)氧)-丙醇 | CAS号288-32-4 咪唑 | CAS号627-18-9 3-溴-1-丙醇 | CAS号820224-57-5 1-[3-[tert-buty... | CAS号78878-05-4 叔丁基(3-碘丙氧基)二甲基硅烷 | CAS号61362-77-4 叔丁基二甲基(戊-4-炔-1-...

3-(叔丁基二甲基硅氧)丙醇置于四溴化碳,三苯基膦体系中,用 二氯甲烷 作为反应溶剂,化学反应 3.0H,以80%的收率获得产物(3-溴丙氧基)叔丁基二甲基硅烷
参考文献:Fournier-Nguefack,Christelle; Lhoste,Paul; Sinou,Denis,Journal Of Chemical Research,Miniprint,1998,# 3,P. 614-634
标题:Fournier-Nguefack,Christelle; Lhoste,Paul; Sinou,Denis,Journal Of Chemical Research,Miniprint,1998,# 3,P. 614-634

专利信息

专利号:US-5705659-A
优先权日:1994-09-30
标 题 :Intermediates for the synthesis of 16-phenoxy-prostatrienoic acid derivatives and a preparing method thereof
发明人：PARK HOKOON; JUNG SUN HO; LEE YONG SUP; NAM KI HONG
权利人:KOREA INST SCI & TECH
摘要:Intermediate compounds represented as formula (I) useful for the synthesis of 16-phenoxy-prostatrienoic acid derivatives and a preparing method thereof are disclosed. ##STR1## wherein R is tetrahydropyranyl, tetrahydrofuranyl, 2-ethoxyethyl, t-butyldimethylsilyl, triisopropylsilyl or triethylsilyl group; R 1 and R 2 are independently hydrogen or ester-forming group; P is hydrogen, trimethylsilyl or tri-n-butyltin; and wavy line means epi-stereoisomeric mixture.

专利号:US-7417139-B2
优先权日:2003-08-30
标 题 :Method for polynucleotide synthesis
发明人：DELLINGER DOUGLAS J; SIERZCHALA AGNIESZKA B; CARUTHERS MARVIN H; DELLINGER GERALDINE F
权利人:AGILENT TECHNOLOGIES INC
摘要:Methods of forming an internucleotide bond are disclosed. Such methods find use in synthesis of polynucleotides. The method involves contacting a functionalized support with a precursor having an exocyclic amine triaryl methyl protecting group under conditions and for a time sufficient to result in internucleotide bond formation. The functionalized support includes a solid support, a triaryl methyl linker group, and a nucleoside moiety having a reactive site hydroxyl, the nucleoside moiety attached to the solid support via the triaryl methyl linker group. In particular embodiments, the precursor has the structure: n nwherein:n O and H represent oxygen and hydrogen, respectively R1 is hydrido, hydroxyl, protected hydroxyl, lower alkyl, modified lower alkyl, or alkoxy, one of R2 or R3 is a hydroxyl protecting group; and the other of R2 or R3 is a reactive group capable of reacting with the reactive site hydroxyl, Base is a heterocyclic base having an exocyclic amine group, and Tram is the exocyclic amine triaryl methyl protecting group.

专利号:US-7211598-B2
优先权日:2002-06-28
标 题:Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
发明人：GARVEY DAVID S; RANATUNGE RAMANI R; RICHARDSON STEWART K
权利人:NITROMED INC
摘要:The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors having at least one oxime group or hydrazone group and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor having at least one oxime group or hydrazone group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor having at least one oxime group or hydrazone group, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention having at least one oxime group or hydrazone group can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

专利号:US-7442802-B2
优先权日:2002-06-27
标 题:Cyclooxygenase-2 selective inhibitors, compositions and methods of use
发明人：BANDARAGE UPUL K; EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; KHANAPURE SUBHASH P; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

专利号:US-6593347-B2
优先权日:1998-10-30
标题 :Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
发明人：BANDARAGE UPUL K; DONG QING; FANG XINQIN; GARVEY DAVID S; MERCER GREGORY J; RICHARDSON STEWART K; SCHROEDER JOSEPH D; WANG TIANSHENG
权利人:NITROMED INC
摘要:The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

专利号:US-7432285-B2
优先权日:1999-12-23
标 题 :Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
发明人：BANDARAGE RAMANI R; BANDARAGE UPUL K; FANG XINQIN; GARVEY DAVID S; LETTS L GORDON; SCHROEDER JOSEPH D; TAM SANG W
权利人:NITROMED INC
摘要:The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.